All In Biotech

Drug Trial Radar · NCT06189404

Effect of Tigulixostat on the Pharmacokinetics of Theophylline

A Phase 1, Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of Multiple Oral Doses of Tigulixostat on the Pharmacokinetics of a Single Oral Dose of Theophylline

Last checked: Nov 20, 2026Latest source record: Jan 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Oct 31, 2023

Primary completion

Nov 13, 2023

Study completion Nov 30, 2023

Sponsor

Lead sponsor
LG ChemIndustry
Sponsor type
Industry
First posted
Jan 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A phase 1, open-label, drug-drug interaction study to evaluate the effect of multiple doses of tigulixostat on the pharmacokinetics of single-dose theophylline in healthy adult volunteers.

Conditions

  • Gout
  • Hyperuricemia

Interventions

  • TigulixostatDrug

    300 mg oral dose

  • TheophyllineDrug

    400 mg oral dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC0-t of theophylline with and without tigulixostatTime frame: Up to 72 hours
  2. AUC0-inf of theophylline with and without tigulixostatTime frame: Up to 72 hours
  3. Cmax of theophylline with and without tigulixostatTime frame: Up to 72 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PPD - Austin Research Unit

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.